Jun
09

Volkin, Srivastava named KU’s second, third Eminent Scholars

Kansas Bioscience Authority commits $4.3 million to support professors A prominent pharmaceutical scientist with 20 years of industrial research and development experience joined the KU faculty earlier this month, thanks in part to a five-year, $2.5 million financial commitment from the Kansas Bioscience Authority. David Volkin comes to KU from Centocor R&D, a subsidiary of […]

Jun
09

Research discovers potential new Rx target for colon cancer

SATB2 is a novel “transcription factor” – a protein “switch” that controls which genes are turned on or off inside a cancer cell. Drs. Rakesh Srivastava and Sharmila Shankar identified it in the so-called “cancer stem cells” – cancer cells that behave like stem cells. Cancer stem cells are a small subset of immortal cells in tumors that are […]

Jun
09

Protein that turns normal cells into cancer stem cells offers target to fight colon cancer

Colon cancer is a global killer. Each year more than one million people worldwide are diagnosed with it; more than half a million die from it. If diagnosed early enough the standard treatment involves surgery, chemotherapy, radiation or targeted drug therapy to destroy the tumors. In many cases this may work. But in some cases, […]

 

 

Archives